Top

Published in:

01-04-2012

Outcome of Operative Therapy of Hepatic Metastatic Stomach Carcinoma: A Retrospective Analysis

Authors: Claus W. Schildberg, R. Croner, S. Merkel, V. Schellerer, V. Müller, S. Yedibela, W. Hohenberger, G. Peros, A. Perrakis

Published in: World Journal of Surgery | Issue 4/2012

Abstract

Background

In general, hepatic metastasis from stomach carcinoma has an unfavorable prognosis. In addition, there are often further metastases in other organs, such as peritoneal carcinomatosis. The major aim of the present study was to investigate a potential curative surgical approach in these patients.

Material and methods

Thirty-one patients with hepatic metastases from stomach cancer were treated in the University Clinic Erlangen-Nürnberg. The data were collected retrospectively from 1972 to 1977 and prospectively since 1978 at the Erlangen Cancer Registry. The time frame of this retrospective analysis from patients who had surgical resection of hepatic metatases from gastric cancer was from 1972 to 2008. The median age of the patients was 65 years, and the ratio of men to women was 2:1.

Results

Atypical or anatomical resections of segments were possible in 21 cases. Larger operations, such as hemihepatectomy (right/left), were performed in 10 patients. The postoperative complication rate was 29%, and the hospital mortality was 6%. The five-year survival rate was 13%; R0 resection was achieved in 23 patients. We also found a significant difference in the 5-year survival rate between synchronous and metachronous metastases (0 vs. 29%; p < 0.001) and R0 resected patients (p = 0.002). Patients with solitary metastases had a significantly better median survival than patients with multiple metastases (21 vs. 4 months; p < 0.005.)

Conclusions

The overall survival in our study was 13%; therefore gastric cancer with liver metastases is not in every case a palliative situation. It seems that patients with liver metastases benefit from resection, especially if the metastases are metachronous (p < 0.001) and solitary, provided that a curative R0 resection has been achieved. An interdisciplinary approach with neoadjuvant chemotherapy appears useful. Additional controlled studies should be conducted.

Al-Batran SE, Hartmann J, Probst S, Arbeitsgemeinschaft Internistische Onkologie et al (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26:1435–1442PubMedCrossRef

Schmiegel W, Reinacher-Schick A, Arnold D et al (2008) Update S3-guideline “colorectal cancer” 2008. Z Gastroenterol 46:799–840 [in German]PubMedCrossRef

Ojima H, Ootake S, Yokobori T et al (2007) Treatment of multiple liver metastasis from gastric carcinoma. World J Surg Oncol 5:70PubMedCrossRef

Kutlu R, Sarac K, Yilmaz S et al (2005) Percutaneous right portal vein embolization with polyvinyl alcohol particles in gastric cancer metastasis: report of a case. Surg Today 35:765–769PubMedCrossRef

Scheele J, Altendorf-Hofmann A, Grube T (2001) Resection of colorectal liver metastases: which prognostic factors should govern patient selection? Chirurg 72:547–560PubMedCrossRef

Choti MA, Sitzmann JV, Tiburi MF et al (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759–766PubMedCrossRef

Fong Y, Cohen AM, Fortner JG et al (1997) Liver resection for colorectal metastases. J Clin Oncol 15:938–946PubMed

Goldsmith NA, Woodburne RT (1957) The surgical anatomy pertaining to liver resection. Surg Gynecol Obstet 105:310–318PubMed

Makino H, Kunisaki C, Izumisawa Y et al (2010) Indication for hepatic resection in the treatment of liver metastasis from gastric cancer. Anticancer Res 30:2367–2376PubMed

10.

Yedibela S, Göhl J, Graz V et al (2005) Changes in indication and results after resection of hepatic metastases from noncolorectal primary tumors: a single-institutional review. Ann Surg Oncol 12:778–785PubMedCrossRef

11.

Laurent C, Rullier E, Feyler A et al (2001) Resection of noncolorectal and nonneuroendocrine liver metastases: late metastases are the only chance of cure. World J Surg 25:1532–1536. doi:10.1007/s00268-001-0164-7 PubMed

12.

Lindell G, Ohlsson B, Saarella A et al (1998) Liver resection of noncolorectal secondaries. J Surg Oncol 69:66–70PubMedCrossRef

13.

Maksan SM, Lehnert T, Bastert G et al (2000) Curative liver resection for metastatic breast cancer. Eur J Surg Oncol 26:209–212PubMedCrossRef

14.

Sakamoto Y, Ohyama S, Yamamoto J et al (2003) Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. Surgery 133:507–511PubMedCrossRef

15.

Van Ruth S, Mutsaerts E, Zoetmulder FAN et al (2001) Metastasectomy for liver metastases of non-colorectal primaries. Eur J Surg Oncol 27:662–667PubMedCrossRef

16.

Elias D, Cavalcanti de Albuqueque A, Eggenspieler P et al (1998) Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg 187:487–493PubMedCrossRef

17.

Harrison LE, Brennan MF, Newman E et al (1997) Hepatic resection for noncolorectal, nonneuroendocrine metastases: a fifteen-year experience with ninety-six patients. Surgery 121:625–632PubMedCrossRef

18.

Okano K, Maeba T, Ishimura K et al (2002) Hepatic resection for metastatic tumors from gastric cancer. Ann Surg 235:86–91PubMedCrossRef

19.

Ambiru S, Miyazaki M, Ito H et al (2001) Benefits and limits of hepatic resection for gastric metastases. Am J Surg 181:279–283PubMedCrossRef

20.

Hwang SE, Yang DH, Kim CY et al (2009) Prognostic factors for survival in patients with hepatic recurrence after curative resection of gastric cancer. World J Surg 33:1468–1472. doi:10.1007/s00268-009-0034-2 PubMedCrossRef

21.

Adam R, Chiche L, Aloia T et al (2006) Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg 244:524–535PubMedCrossRef

22.

Kakeji Y, Morita M, Maehara Y et al (2010) Strategies for treating liver metastasis from gastric cancer. Surg Today 40:287–294PubMedCrossRef

23.

Cheon SH, Rha SY, Jeung HC et al (2008) Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol 19:1146–1153PubMedCrossRef

24.

Tsujimoto H, Ichikura T, Ono S et al (2010) Outcomes for patients following hepatic resection of metastatic tumors from gastric cancer. Hepatol Int 4:406–413PubMedCrossRef

25.

Tiberio GA, Coniglio A, Marchet A et al (2009) Metachronous hepatic metastases from gastric carcinoma: a multicentric survey. Eur J Surg Oncol 35:486–491PubMedCrossRef

26.

Chau I, Norman A, Cunningham D et al (2004) Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer—pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22:2395–2403PubMedCrossRef

27.

Zacherl J, Zacherl M, Scheuba C et al (2002) Analysis of hepatic resection of metastasis originating from gastric adenocarcinoma. J Gastrointest Surg 6:682–689PubMedCrossRef

28.

Choi SB, Song J, Kang CM et al (2010) Surgical outcome of metachronous hepatic metastases secondary to gastric cancer. Hepatogastroenterology 57:29–34PubMed

29.

Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) V325 Study Group Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991–4997PubMedCrossRef

30.

Nishiyama M, Wada S (2009) Docetaxel: its role in current and future treatments for advanced gastric Cancer. Gastric Cancer 12:132–141PubMedCrossRef

31.

Al-Batran SE, Hartmann JT, Hofheinz R et al (2008) Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 19:1882–1887PubMedCrossRef

32.

Vecchione L, Orditura M, Ciardiello F et al (2009) Novel investigational drugs for gastric cancer. Expert Opin Investig Drugs 18:945–955PubMedCrossRef

Title: Outcome of Operative Therapy of Hepatic Metastatic Stomach Carcinoma: A Retrospective Analysis
Authors: Claus W. Schildberg
R. Croner
S. Merkel
V. Schellerer
V. Müller
S. Yedibela
W. Hohenberger
G. Peros
A. Perrakis
Publication date: 01-04-2012
Publisher: Springer-Verlag
Published in: World Journal of Surgery / Issue 4/2012
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-012-1492-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Outcome of Operative Therapy of Hepatic Metastatic Stomach Carcinoma: A Retrospective Analysis

Abstract

Background

Material and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Material and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2012

Retromuscular Mesh Repair of Midline Incisional Hernia with Polyester Standard Mesh: Monocentric Experience of 261 Consecutive Patients with a 5-year Follow-up

Pancreatectomy Combined with Superior Mesenteric Vein–Portal Vein Resection for Pancreatic Cancer: A Meta-analysis

Comparison of Dexamethasone with Ondansetron or Haloperidol for Prevention of Patient-Controlled Analgesia-Related Postoperative Nausea and Vomiting: A Randomized Clinical Trial

Polyacrylamide Gel Injections for Breast Augmentation: Management of Complications in 106 Patients, a Multicenter Study

Outcome Following Management of Dysphagia after Laparoscopic Anti-reflux Surgery

The Evolution of Breast Reconstruction: A Historical Perspective